非小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂原发性耐药研究进展
肺癌是全球最常见的癌症之一,非小细胞肺癌(NSCLC)约占全部肺癌的80%。晚期NSCLC化疗仅轻微改善总生存,而表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)对晚期NSCLC显示出强效。然而仅部分具有EGFR基因突变的NSCLC患者对EGFR TKIs敏感,无EGFR突变者表现为先天耐药,约20%-30%的EGFR突变患者对EGFR TKIs也无应答。本文综述晚期NSCLC,尤其是EGFR敏感突变患者对EGFR TKIs原发性耐药的机制。
要点
- NSCLC约占全部肺癌的80%,晚期患者化疗仅轻微改善总生存。
- EGFR TKIs对晚期NSCLC显示强效,但仅部分EGFR突变患者敏感。
- 约20%-30%的EGFR突变患者对EGFR TKIs无应答,存在原发性耐药。
核心结论
- 本文综述了晚期NSCLC尤其是EGFR敏感突变患者对EGFR TKIs原发性耐药的机制。
研究设计与样本
- 本文为综述,汇总晚期NSCLC对EGFR TKIs原发性耐药机制的研究进展。
主要发现
- NSCLC约占全部肺癌的80%。
- 晚期NSCLC化疗仅轻微改善总生存。
- 仅有某些EGFR基因突变的NSCLC患者对EGFR TKIs敏感。
- 无EGFR突变的患者对EGFR TKIs表现为先天耐药。
- 约20%-30%的EGFR突变患者对EGFR TKIs也无应答。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer is one of the most common cancers worldwide. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. Chemotherapy for patients with advanced NSCLC has only marginally improved overall survival; whereas recently developed small-molecule compound epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrate strong efficacy in treating advanced NSCLC. However, only a part of patients with NSCLC is sensitive to the treatment of EGFR TKIs if they have certain mutations of EGFR gene in their tumors. Patients without EGFR mutations show innate resistance to EGFR TKIs. Furthermore, approximately 20%-30% of patients with EGFR mutations also do not response to EGFR TKIs. In this review, the mechanisms underlying the primary resistance to EGFR TKIs in advanced NSCLC, especially in those with EGFR sensitive mutations, are summarized.
引用
- Yao YF, Wang J, Wang BC, et al. [Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998436. doi:10.3760/cma.j.issn.0253-3766.2016.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。